Programmed cell-death 1 ligand 1 (PD-L1) is a protein of the B7/CD28 family that controls T-cell activation, and MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody, may be a promising therapeutic approach for the treatment of cancer [30]. Here, CD274 is linked to cancer.